Elegen is a company that provides NGS verified, cell-free DNA synthesis with linear DNA from 1 to 7kb, offering high accuracy and fast delivery for synthetic biology workflows.

Elegen

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale.

To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges.

Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success. 

Sahsen Ventures

Alix Ventures

ELEGEN

#TeamElegen welcomes @Tony Cox, Ph.D. as Principal Scientist! Tony brings extensive #synbio experience and a proven record of conceiving, developing and implementing innovative solutions on both an experimental and commercial high-throughput scale - a great fit for advancing ELEGEN's next-gen ENFINIA DNA scaleup development! #WelcometotheTeam, Tony!

#hiring #growing #BayAreaJobs #SanFrancisco #employeeappreciation

The RNA Therapeutics - From Concept to Clinic Conference is in full swing!  Stop by ELEGEN Booth 12 to learn about ENFINIA next-generation DNA - long, complex, clonal-quality DNA, shipped in 6-8 days and ready for direct use in your workflows, no cloning required. You can reliably count on ENFINIA DNA to meet your deadlines.

#RNAtherapeutics #nextgenDNA #EnfiniaDNA #mRNAvaccines RNA Therapeutics Institute at UMass Chan Medical School #RNATx

Join the team that is making next-gen DNA a reality! Our R&D and Operations groups continue to grow. Innovative technology, great culture, awesome people. Check out our open positions & apply: https://hubs.ly/Q02CP7vc0

#synbio  #biotech #SanFrancisco #BayAreaJobs #Hiring

Yesterday was International Women in Engineering Day, but we celebrate these women and the awesome skills they bring to #TeamElegen and #cellfreesynthesis every day! We ♥️ their knowledge, dedication, passion, and teamwork that enhance our products, technology, and work culture. 👏🎉

#INWED24 #EnhancedbyEngineering 
Marion Meunier, Nadiya Sitdykova, Iris HC Lin, Nidhi Gupta,
Radhika Dalal, Kellie King, Sukhvinder Kaur, Galit Meshulam-Simon

ENFINIA DNA is #NextGen DNA:
✅ Long (≤7 kb)
✅ NGS-verified
✅ High complexity
✅ ≥95% purity
✅ Reliable, fast turnaround (6-8 days)

With our cell-free DNA production tech, ENFINIA linear DNA ships ready-to-use with minimal or no cloning. 

ELEGEN's not your grandfather’s gene synthesis provider. 

Ready to get started? https://hubs.ly/Q02CvsCL0
#genesynthesis #EnfiniaDNA #cellfreesynthesis #DNAinnovation

This month’s #EmployeeSpotlight is on Kellie King, Sr. Research Associate. Working on the molecular biology team, she loves testing new ideas and streamlining processes to be as efficient as possible. We're #LuckytoHaveYou on #TeamElegen!👏🎉

Learn more about Kelly: https://bit.ly/3RBa0R3

#EmployeeAppreciation #BayAreaJobs

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 3:29 AM	939faf54
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 18, 2024 3:29 AM	cfdd457f
translate crunchbase fundingrounds	general
peers	general	Jul 18, 2024 3:29 AM	3ebf6557
news basic	general	Jul 18, 2024 3:29 AM	95ddc4cf
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ELEGENBIO

Elegen